

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 24D0400666	(X3) Date Survey Completed 10/19/2022
Name of Provider or Supplier Centracare - Monticello Hospital	Street Address, City, State 1013 Hart Blvd, Monticello, MN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: . Based on a review of Center for Medicare and Medicaid Services reports and American Proficiency Institute (API) proficiency testing reports, the laboratory failed to successfully participate in proficiency testing (PT) under the subspecialty of ABO/RHO. Findings include: 1. The CASPER Report 0155D, reviewed on October 13, 2022, indicated the the laboratory failed to successfully participate in ABO/RHO PT in 2021 and 2022. Findings are as follows: D2153 - the laboratory failed to obtain a PT score of at least 100 percent for ABO Type testing D2154 - the laboratory failed to obtain an overall testing event score of at least 100 percent for the ABO/RHO Subspecialty D2162 - the laboratory failed to achieve satisfactory analyte PT</p>

	<p>performance for ABO Type testing in two out of three consecutive events D2163 - the laboratory failed to achieve satisfactory performance for the ABO/RHO Subspecialty in two out of three consecutive events .</p>
D2153	<p>ABO GROUP AND D(RHO) TYPING CFR(s): 493.859(a)</p> <p>Failure to attain a score of at least 100 percent of acceptable responses for each analyte or test in each testing event is unsatisfactory analyte performance for the testing event.</p> <p>This STANDARD is not met as evidenced by: . Based on review of proficiency testing (PT) reports from the American Proficiency Institute (API), the laboratory failed to obtain a PT score of at least 100 percent for ABO Type testing which resulted in unsatisfactory performance for the analyte. Unsatisfactory PT performance of ABO Type testing was obtained in the following events. - 2021 3rd event 90% - 2022 2nd event 0% .</p>
D2154	<p>ABO GROUP AND D(RHO) TYPING CFR(s): 493.859(b)</p> <p>Failure to attain an overall testing event score of at least 100 percent is unsatisfactory performance.</p> <p>This STANDARD is not met as evidenced by: . Based on review of proficiency testing (PT) reports from the American Proficiency Institute (API), the laboratory failed to obtain a PT score of at least 100 percent for the ABO/RHO Subspecialty which resulted in overall unsatisfactory performance in the Subspecialty. Overall unsatisfactory PT performance for the ABO/RHO Subspecialty was obtained in the following API events: - 2021 3rd event 80% - 2022 2nd event 0% .</p>
D2162	<p>ABO GROUP AND D(RHO) TYPING CFR(s): 493.859(f)</p> <p>Failure to achieve satisfactory performance for the same analyte in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: . Based on review of proficiency testing (PT) reports from the American Proficiency Institute (API), the laboratory failed to achieve satisfactory analyte PT performance for ABO Type testing in two out of three consecutive testing events which led to unsuccessful performance for the analyte. API results indicated the laboratory had unsatisfactory performance for ABO Type testing in two out of three consecutive events leading to unsuccessful performance for the analyte. Unsatisfactory PT performance of ABO Type testing was obtained in the following events. - 2021 3rd event 90% - 2022 2nd event 0% .</p>
D2163	<p>ABO GROUP AND D(RHO) TYPING</p>

CFR(s): 493.859(g)

Failure to achieve an overall testing event score of satisfactory for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

. Based on review of proficiency testing (PT) reports from the American Proficiency Institute (API), the laboratory failed to achieve satisfactory performance for the ABO/RHO Subspecialty in two out of three consecutive testing events which led to unsuccessful PT performance in the Subspecialty. API reports indicated the laboratory had unsatisfactory performance for the ABO/RHO Subspecialty in two out of three consecutive events leading to unsuccessful PT performance for Subspecialty. Unsatisfactory PT performance for the ABO/RHO Subspecialty was obtained in the following API events. - 2021 3rd event 80% - 2022 2nd event 0% .